Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Phototoxicity.

Subjects phototypes I to IV (according to Fitzpatrick classification). The products is applied over semi-occlusive dressings, remaing in contact with the skin.

Inclusion criteria

• Healthy participants;
• Non-injured skin in the test region;
• Agreement to adhere to the test procedures and requirements and to attend the institute on the day(s) and at the time(s) determined for the evaluations;
• Ability to consent to participation in the study;
• Phototype (Fitzpatrick): II and III;

Exclusion criteria

• Pregnant or breastfeeding women;
• Use of the following systemic drugs: antihistamines, non-hormonal anti-inflammatory drugs and corticoids;
• History of allergy to cosmetics, topical products or research product;
• Localized or widespread dermatological diseases or inflammatory dermatoses active and nerve damage in the test region;
• Personal or family pathological history of skin cancer;
• Use of topical or systemic photosensitizing medication;
• History of phototoxic, photoallergic reactions, dermatoses caused by light, atopy, pathologies aggravated or triggered by ultraviolet radiation;
• Photo-induced pathologies;
• Frequent exposure to the sun or tanning chambers;
• Participated in an allergenicity study in a period of less than 4 weeks from the start of the study;
• Skin marks in the experimental area that interfere with the evaluation of possible reactions;
• Active dermatoses;
• Forecast to take a bath in the sea, pool or sauna during the study;
• Participants who play water sports;
• Dermography;
• Use of the following topical or systemic drugs: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs and corticoids up to 2 weeks prior to selection or, considering deposit corticoids, the interval shall be 1 month prior to selection;
• Treatment with acid vitamin A and/or its derivatives via oral or topical until

1 month before the beginning of the study;

• Aesthetic and/or body dermatological treatment until 3 weeks before selection;
• Vaccination during the study or until 3 weeks before the study;
• Being participated in another clinical trial.